Phase I study of weekly bortezomib for patients with recurrent or refractory multiple myeloma
Not Applicable
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000002922
- Lead Sponsor
- PO IB-HOPE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) CNS involvement 2) History of severe drug allergy 3) Active infectious diseases 4) HBs antigen or HCV antibody or HIV antibody positive 5) Significant complications which include cardiac dysfunction, liver cirrhosis, uncontrolled diabetes, renal failure 6) Interstitial pneumonitis 7) History of other active malignancy 8) Severe mental disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The dose-limiting toxicity of weekly bortezomib during the first cycle.
- Secondary Outcome Measures
Name Time Method Response rate, progression-free survival, overall survival, and adverse effects.